paliperidone palmitate · Janssen Pharms · NDA 207946
Invega Trinza
Earliest generic entry, as listed · earliest of 4 marketed strengths
5 Apr 2036
Blocked by patent: US 10143693, US 10143693. Only method-of-use patents remain, so a generic may carve out the protected indication and enter earlier.
Listed patents · 2 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 10143693 | use U-2457 | 5 Apr 2036 |
| US 10143693 | use U-2458 | 5 Apr 2036 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 4
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 207946 · 001 · RLD | suspension, extended release, intramuscular | 273MG/0.875ML (273MG/0.875ML) | 5 Apr 2036 |
| 207946 · 002 · RLD | suspension, extended release, intramuscular | 410MG/1.315ML (311.79MG/ML) | 5 Apr 2036 |
| 207946 · 003 · RLD | suspension, extended release, intramuscular | 546MG/1.75ML (312MG/ML) | 5 Apr 2036 |
| 207946 · 004 · RLD | suspension, extended release, intramuscular | 819MG/2.625ML (312MG/ML) | 5 Apr 2036 |